Leeward Investments LLC MA Increases Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Leeward Investments LLC MA raised its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 7.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 405,506 shares of the life sciences company's stock after acquiring an additional 29,402 shares during the quarter. Leeward Investments LLC MA owned 0.53% of Integra LifeSciences worth $9,197,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. KBC Group NV lifted its stake in shares of Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock valued at $52,000 after purchasing an additional 1,120 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after buying an additional 2,800 shares during the last quarter. Empowered Funds LLC acquired a new stake in Integra LifeSciences in the 4th quarter valued at about $180,000. Romano Brothers AND Company purchased a new position in Integra LifeSciences during the 4th quarter valued at about $204,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. acquired a new position in Integra LifeSciences during the fourth quarter worth about $204,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Morgan Stanley assumed coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target for the company. Citigroup lifted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $23.00.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares of the company's stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.10% of the company's stock.

Integra LifeSciences Trading Down 4.5 %

NASDAQ IART traded down $1.12 during trading hours on Wednesday, hitting $23.60. 992,944 shares of the company's stock were exchanged, compared to its average volume of 611,115. The business's 50 day moving average is $23.71 and its 200-day moving average is $21.83. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $44.69. The firm has a market capitalization of $1.82 billion, a P/E ratio of -262.19, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.89 EPS. As a group, analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.